InsidersTradesSigma
Track the DIANTHUS THERAPEUTICS INC stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €5.9bn. The latest transaction was disclosed on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ANNE M MCGEORGE. The full history is openly available.
Analysts rate DIANTHUS THERAPEUTICS INC Strong Buy (bullish), based on 13 analysts. Average price target: US$137.62.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
DIANTHUS THERAPEUTICS INC is a company focused on developing innovative therapies for cancer treatment. It specializes in research and the development of targeted therapeutic solutions.